Lu-Hao Li

Lu-Hao Li

Auto-generated profile, based on publicly available information

Lu-Hao Li

The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2026 in Annals of Medicine
Verified
Journal Article
Open access
LLLu-Hao Li
Lu-Hao Li
YHYi Huang
Yi Huang
XWXiao-Xiang Wang
Xiao-Xiang Wang
CXCheng-Cheng Xu
Cheng-Cheng Xu
LWLei Wu
Lei Wu
RMRuijie Ma
Ruijie Ma
Neurodegenerative diseases are complex disorders characterized by the progressive loss of neuronal structure and function, involving pathological mechanisms such as oxidative stress, chronic inflammation, protein misfolding, and impaired synaptic plasticity. Recent studies have revealed that epigenetic regulation plays a critical role in the onset and progression of these diseases, including mechanisms such as DNA methylation, histone modifications, and non-coding RNA regulation. Natural polyphenolic compounds, known for their safety and multi-target properties, have emerged as promising candidates for neuroprotection and therapeutic intervention. This review summarizes recent advances in the neuroprotective effects of polyphenols in neurodegenerative diseases through epigenetic mechanisms. It focuses on their regulation of DNA methyltransferase activity, histone acetylation status, and non-coding RNA expression, as well as their influence on neurotrophic factors, inflammatory mediators, and synapse-related gene expression. Polyphenolic compounds such as curcumin, resveratrol, and epigallocatechin gallate (EGCG) have been shown to modulate epigenetic enzyme activity, alleviate neuroinflammation, improve mitochondrial function, and promote neuroregeneration, demonstrating multi-level neuroprotective effects. However, clinical translation is limited by low oral bioavailability, rapid metabolism, and insufficient brain-targeting capacity. Emerging strategies including nano-delivery systems, prodrug design, and omics technologies hold promise in overcoming these limitations and enhancing therapeutic efficacy. Polyphenols exert multi-target regulatory effects via epigenetic mechanisms in neurodegenerative diseases, showing great potential for intervention. In the future, integrating precision nutrition, personalized treatment, and multi-omics approaches may facilitate the development of novel epigenetic-based strategies for the prevention and treatment of neurodegenerative disorders.

25 March 2026 in Annals of Medicine
Verified
Journal Article
Open access
LLLu-Hao Li
Lu-Hao Li
JZJie-Qi Zhang
Jie-Qi Zhang
XYXi-Han Ying
Xi-Han Ying
YHYi Huang
Yi Huang
CXCheng-Cheng Xu
Cheng-Cheng Xu
RMRuijie Ma
Ruijie Ma
Spinal cord injury (SCI) is a severe neurological disorder involving a two-phase pathological process. The primary injury results from direct mechanical trauma, while the secondary injury includes a cascade of cellular and molecular events such as excitotoxicity, oxidative stress, and inflammation. Recent studies have highlighted cuproptosis, a novel form of copper-dependent regulated cell death, as a significant contributor to secondary injury and immune dysregulation. To summarize current research on cuproptosis in the context of spinal cord injury, clarify its molecular mechanisms and immunological effects, and explore its potential as a therapeutic target. Relevant experimental and review studies were identified through database searches using keywords including cuproptosis, spinal cord injury, copper homeostasis, and regulated cell death. The review focuses on molecular mechanisms, mitochondrial dysfunction, immune responses, and key regulators such as FDX1, DLAT, ATP7A, and CTR1. Following spinal cord injury, disruption of the blood-spinal cord barrier and inflammatory responses lead to copper accumulation, triggering cuproptosis. This process causes protein aggregation, mitochondrial dysfunction, and cell death, particularly in neurons, oligodendrocytes, and activated immune cells. During the acute phase, cuproptosis intensifies neuronal loss and inflammation. In the chronic phase, it may help eliminate persistently activated cells and contribute to scar remodeling. Cuproptosis also interacts with other forms of regulated cell death, such as pyroptosis and ferroptosis. Cuproptosis plays an important role in SCI secondary injury and immune microenvironment remodeling. Targeting cuproptosis related pathways and restoring copper homeostasis may provide promising strategies for precision therapy.